Insulet Corp stock (US45784P1012): Hits 52-week low at $148.24

Insulet Corp (NASDAQ:PODD) shares reached a 52-week low of $148.24 USD recently, amid strong Q4 2025 earnings showing 31.2% revenue growth to $783.8 million. Capital Research holds 2.4% stake per latest SEC filing.

Insulet Corp shares hit a 52-week low of 148.24 USD, according to Investing.com as of May 2026. This comes after robust Q4 CY2025 results, with revenue surging 31.2% year-over-year to $783.8 million, beating estimates by 2%, per StockStory as of early 2026. Adjusted EPS of $1.55 exceeded forecasts by 6%. Separately, Capital Research Global Investors amended its Schedule 13G/A filing on March 31, 2026, disclosing a 2.4% passive stake of 1,669,556 shares, as reported in StockTitan SEC filing summary.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Insulet Corporation
• Sector/industry: Healthcare / Medical Devices
• Headquarters/country: United States
• Core markets: US and international diabetes care
• Key revenue drivers: Omnipod insulin delivery systems
• Home exchange/listing venue: Nasdaq (PODD)
• Trading currency: USD

Insulet Corp: core business model

Insulet Corp develops, manufactures, and sells innovative insulin delivery systems for people with diabetes, primarily through its flagship Omnipod tubeless insulin pump technology. The company focuses on automated insulin delivery solutions that improve patient outcomes and quality of life, according to its investor relations site. Omnipod products are used by insulin-dependent patients in the US and internationally, with a strong emphasis on user-friendly, wearable devices that eliminate traditional tubing.

Insulet's model centers on recurring revenue from disposable Pods and personalized insulin management systems. The company reported market share gains with 26.3% annual revenue growth over the last two years, as noted in StockStory analysis as of early 2026. This positions Insulet as a leader in the growing diabetes management sector, relevant for US investors tracking healthcare innovation.

Main revenue and product drivers for Insulet Corp

Key revenue comes from Omnipod sales, with Q4 CY2025 revenue at $783.8 million, up 31.2% year-over-year and beating analyst estimates of $768.2 million (reporting period ending December 2025, published early 2026), per StockStory as of early 2026. Adjusted EBITDA reached $194 million (24.8% margin), surpassing forecasts. Management guides for 26% year-on-year sales growth in the next quarter.

In Q1 2025 (reported later), net income rose 157% to $91.1 million with a 12% profit margin, driven by higher revenue, according to Simply Wall St as of 2026. Constant currency revenue grew 29% year-over-year in Q4. These metrics underscore Omnipod's role as the primary driver, with US market exposure making it pertinent for American portfolios.

Industry trends and competitive position

The diabetes care market is expanding due to rising prevalence, with Insulet benefiting from demand for tubeless, automated delivery systems. Its 31.2% revenue growth in Q4 CY2025 outpaced peers, highlighting competitive strength in insulin pumps versus traditional methods. US investors note Insulet's Nasdaq listing and focus on the large American diabetes population.

Why Insulet Corp matters for US investors

Listed on Nasdaq (PODD), Insulet offers US investors direct exposure to medical device innovation in diabetes management, a sector with steady demand tied to the US healthcare economy. Recent earnings beats and a $17.33 billion market cap (as of early 2026 per StockStory) signal growth potential amid demographic trends.

Conclusion

Insulet Corp demonstrated solid Q4 CY2025 performance with revenue and EPS beats, alongside a recent 52-week low and passive stake disclosure by Capital Research. These developments reflect operational strength in diabetes care, though shares face near-term pressure. US investors may track upcoming quarters for sustained growth trends in this Nasdaq-listed name.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.